Skip to main content

PRELUDE CAPITAL MANAGEMENT, LLC

Position in NVO — Novo Nordisk A S

CIK 1387508 NEW YORK, NY

Position in NVO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$230,879
-$169,575 QoQ
Shares Held
4,816
-17.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#977
of 1,348 holders
Holding Since
Dec 2020
17 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in NVO Over Time

Shares Held

Position Value (USD)

Derivatives in NVO

reported options exposure · as of Jun 30, 2026
CallValue
$34,884
CallShares
15,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

PRELUDE CAPITAL MANAGEMENT, LLC holds $9,540,290 across 6 Drug Manufacturers - General names. NVO ranks #6 (2.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
6 NVO
Novo Nordisk A S
This page
4,816 $230,879

All Filings in NVO

Export CSV
19 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $34,884 15,300
2026-06-30 $230,879 4,816
2025-06-30 $400,454 5,802
2025-03-31 $1,195,340 17,214
2024-12-31 $283,866 3,300
2024-09-30 $641,787 5,390
2024-06-30 $300,039 2,102
2023-12-31 $1,163,502 11,247
2023-09-30 $545,640 6,000
2023-06-30 $1,188,641 7,345
2023-03-31 $1,607,314 10,100
2022-12-31 $1,295,609 9,573
2022-09-30 $1,207,216 12,117
2021-12-31 $885,248 7,904
2021-09-30 $697,992 7,270
2021-06-30 $50,262 600
2021-06-30 $480,923 5,741
2021-03-31 $384,765 5,707
2020-12-31 $321,240 4,599